NeoGenomics (NASDAQ:NEO) Shares Gap Down – What’s Next?

NeoGenomics, Inc. (NASDAQ:NEO) shares gapped down before the market opened on Tuesday . The stock had previously closed at $11.38, but opened at $10.50. NeoGenomics shares last traded at $10.35, with a volume of 853,063 shares trading hands.

More NeoGenomics News

Here are the key news stories impacting NeoGenomics this week:

• Positive Sentiment: Q4 results topped expectations — NeoGenomics reported $0.06 EPS vs. consensus $0.04 and revenue of $190.2M (up ~10.6% YoY), showing continued top-line growth. Read More.
• Positive Sentiment: Product pipeline momentum — NeoGenomics launched PanTracer Pro, a pan-solid tumor assay aimed at speeding genomic profiling and treatment decisions, which could support higher-margin testing over time. Read More.
• Neutral Sentiment: Full disclosure and color available — Management filed the press release, slide deck and earnings call transcript (useful for hearing guidance nuance and margin commentary). Review the call transcript and slides for management’s outlook details. Read More.
• Negative Sentiment: Market focused on guidance and profitability — despite the beat, shares initially fell more than 5% as investors digested FY2026 guidance (revenue range cited roughly $793M–$801M) and ongoing negative margins (reported net margin ~-16% and negative ROE), suggesting the street wanted clearer path to sustained profitability. Read More.
• Negative Sentiment: Analysts remain focused on profitability — coverage notes that while revenue growth continues, converting that into consistent positive EPS and margin improvement is the key driver for re-rating the stock. Read More.

Analyst Upgrades and Downgrades

Several equities research analysts have recently commented on the stock. TD Cowen restated a “buy” rating on shares of NeoGenomics in a research note on Wednesday, January 7th. Needham & Company LLC reissued a “buy” rating and issued a $14.00 price objective on shares of NeoGenomics in a research note on Monday, January 12th. Leerink Partners set a $14.00 target price on NeoGenomics in a research note on Tuesday, October 28th. Zacks Research upgraded shares of NeoGenomics from a “hold” rating to a “strong-buy” rating in a research report on Monday, January 12th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of NeoGenomics in a research report on Monday, December 29th. One equities research analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, six have issued a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Hold” and an average target price of $12.00.

NeoGenomics Stock Up 0.9%

The company has a quick ratio of 3.62, a current ratio of 3.91 and a debt-to-equity ratio of 0.41. The firm has a market cap of $1.49 billion, a P/E ratio of -13.07 and a beta of 1.58. The business has a fifty day moving average of $12.18 and a 200 day moving average of $10.07.

NeoGenomics (NASDAQ:NEO) last announced its quarterly earnings results on Tuesday, February 17th. The medical research company reported $0.06 EPS for the quarter, beating analysts’ consensus estimates of $0.04 by $0.02. NeoGenomics had a negative return on equity of 3.36% and a negative net margin of 16.00%.The company had revenue of $190.17 million during the quarter, compared to analysts’ expectations of $188.25 million. During the same period in the prior year, the business posted $0.04 EPS. NeoGenomics’s revenue was up 10.6% on a year-over-year basis. On average, equities research analysts predict that NeoGenomics, Inc. will post -0.2 EPS for the current year.

Insider Buying and Selling at NeoGenomics

In other NeoGenomics news, COO Warren Stone sold 22,128 shares of the business’s stock in a transaction dated Tuesday, January 20th. The stock was sold at an average price of $12.50, for a total value of $276,600.00. Following the completion of the transaction, the chief operating officer directly owned 121,631 shares of the company’s stock, valued at approximately $1,520,387.50. The trade was a 15.39% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Alicia C. Olivo sold 20,916 shares of NeoGenomics stock in a transaction dated Tuesday, November 25th. The shares were sold at an average price of $12.00, for a total value of $250,992.00. Following the transaction, the executive vice president owned 31,083 shares in the company, valued at $372,996. This trade represents a 40.22% decrease in their position. The disclosure for this sale is available in the SEC filing. Company insiders own 2.40% of the company’s stock.

Institutional Investors Weigh In On NeoGenomics

Institutional investors have recently added to or reduced their stakes in the stock. First Light Asset Management LLC increased its holdings in NeoGenomics by 45.0% during the 3rd quarter. First Light Asset Management LLC now owns 9,927,269 shares of the medical research company’s stock worth $76,639,000 after purchasing an additional 3,080,837 shares in the last quarter. Greenhouse Funds LLLP grew its holdings in shares of NeoGenomics by 57.8% during the second quarter. Greenhouse Funds LLLP now owns 7,431,147 shares of the medical research company’s stock worth $54,322,000 after buying an additional 2,722,823 shares in the last quarter. Loomis Sayles & Co. L P bought a new position in shares of NeoGenomics during the fourth quarter worth about $19,182,000. American Capital Management Inc. raised its position in NeoGenomics by 120.9% in the 3rd quarter. American Capital Management Inc. now owns 2,345,263 shares of the medical research company’s stock valued at $18,105,000 after buying an additional 1,283,390 shares during the last quarter. Finally, Aberdeen Group plc lifted its stake in NeoGenomics by 127.1% in the 4th quarter. Aberdeen Group plc now owns 1,798,939 shares of the medical research company’s stock valued at $21,156,000 after acquiring an additional 1,006,676 shares in the last quarter. 98.50% of the stock is owned by institutional investors.

About NeoGenomics

NeoGenomics, traded on the Nasdaq under the symbol NEO, is a leading provider of cancer-focused genetic and molecular testing services. Headquartered in Fort Myers, Florida, the company operates an integrated network of CAP-accredited and CLIA-certified laboratories across the United States, Europe and Asia. NeoGenomics delivers diagnostic insights that support oncologists, pathologists and healthcare institutions in the detection, prognosis and treatment of hematologic and solid tumor cancers.

The company’s core service offerings include flow cytometry, immunohistochemistry, fluorescence in situ hybridization (FISH), karyotyping and advanced molecular assays such as next-generation sequencing (NGS) panels and polymerase chain reaction (PCR) tests.